Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Paclitaxel-eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus Systematic Implantation of Paclitaxel-eluting Stent for the Treatment of Femoropopliteal de Novo Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01969630
Recruitment Status : Unknown
Verified October 2013 by Leonardo Bolognese, MD, Ospedale San Donato.
Recruitment status was:  Recruiting
First Posted : October 25, 2013
Last Update Posted : October 25, 2013
Sponsor:
Information provided by (Responsible Party):
Leonardo Bolognese, MD, Ospedale San Donato

Brief Summary:
To determine in patients with symptomatic femoropopliteal lesions whether percutaneous revascularization with paclitaxel-eluting balloon angioplasty (PEB) and provisional nitinol stent is superior with respect to the 12-month incidence of restenosis compared to treatment with systematic paclitaxel-eluting stent (PES) angioplasty

Condition or disease Intervention/treatment Phase
Peripheral Artery Disease Device: PEB Device: PES Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : October 2013
Estimated Primary Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angioplasty

Arm Intervention/treatment
Active Comparator: PEB
PEB angioplasty plus provisional nitinol stent implantation
Device: PEB
Paclitaxel eluting balloon angioplasty plus provisional nitinol stent implantation

Experimental: PES
Systematic PES angioplasty
Device: PES
Systematic Paclitaxel eluting stent angioplasty




Primary Outcome Measures :
  1. angiographic binary restenosis [ Time Frame: 12 months ]
    incidence of binary restenosis


Secondary Outcome Measures :
  1. Composite of all cause mortality, major amputation and target lesion revascularization. [ Time Frame: 12 months ]
    incidence of composite endpoint of all cause mortality, major amputation and target lesion revascularization.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • intermittent claudication or critical limb ischemia
  • de novo stenosis ≥ 50% or occlusion of at least 40 mm in length located in femoropopliteal arteries
  • presence of a clear healthy segment between the lesion in superficial femoral and common femoral artery and between popliteal and tibioperoneal trunk
  • presence of at least 1 patent tibial vessel with distal run-off (below-the-knee artery was considered patent if free from obstructive lesions determining angiographic stenosis >70%)

Exclusion Criteria:

  • life expectancy <1 year
  • contraindication for combined antiplatelet therapy or known allergy to nickel or paclitaxel
  • need for major amputation (MA) at the time of enrolment
  • Failure to recanalize intended below-the-knee arteries in CLI patients at risk of major amputation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01969630


Locations
Layout table for location information
Italy
Cardiovascular Department, Ospedale S.Donato Recruiting
Arezzo, AR, Italy, 52100
Contact: Francesco Liistro, MD       francescoliistro@hotmail.com   
Principal Investigator: Leonardo Bolognese, MD, FESC         
Sub-Investigator: Giovanni Falsini, MD         
Sub-Investigator: Paolo Angioli, MD         
Sub-Investigator: Kenneth Ducci, MD         
Principal Investigator: Francesco Liistro, MD         
Sub-Investigator: Simone Grotti, MD         
Sub-Investigator: Italo Porto, MD         
Sponsors and Collaborators
Ospedale San Donato

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Leonardo Bolognese, MD, Director, Ospedale San Donato
ClinicalTrials.gov Identifier: NCT01969630     History of Changes
Other Study ID Numbers: Arezzo011
First Posted: October 25, 2013    Key Record Dates
Last Update Posted: October 25, 2013
Last Verified: October 2013

Keywords provided by Leonardo Bolognese, MD, Ospedale San Donato:
femoropopliteal lesions

Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action